Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (NASDAQ: CADL) reported Q3 2025 results and corporate updates on November 13, 2025. Key clinical progress includes subgroup phase 3 data for CAN-2409 in localized prostate cancer showing improved prostate cancer-specific DFS (HR 0.62; p=0.0046), plans to submit a BLA in Q4 2026, and intent to start a pivotal phase 3 in NSCLC in Q2 2026. Updated survival data for CAN-3110 in recurrent high-grade glioma showed median OS ~11.8–12.0 months in arms A/B. Financially, the company has $87.0M cash (9/30/25) and closed a $130M term loan with $50M drawn at signing to fund operations into Q1 2027.
Candel Therapeutics (Nasdaq: CADL) will present three data sets at SITC 2025 highlighting clinical and preclinical advances in viral immunotherapies and AI‑driven design.
Key points: a Phase 3 study of CAN‑2409 in newly diagnosed, localized prostate cancer met its primary endpoint and the company plans a BLA submission in Q4 2026; Phase 2a MOFA biomarker analysis in NSCLC showed stronger immune activation and prolonged overall survival in non‑squamous vs squamous histology; an AI‑designed candidate (Alpha‑201 IL‑12/15) produced 60.0%±12.6 tumor growth suppression in an EMT6 breast cancer mouse model.
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 from 8:00–8:25 AM GMT (4:00–4:25 AM ET). The presentation will be webcast and available under Events and Presentations in the Investors section at www.candeltx.com. A replay will be archived for up to 90 days after the session.
Candel Therapeutics (Nasdaq: CADL) announced the appointment of Bali Pulendran, Ph.D. to its Research Advisory Board on October 16, 2025. Dr. Pulendran is a systems immunology and vaccinology expert, Violetta L. Horton Professor at Stanford, Director of the Institute for Immunity, Transplantation and Infection, and a Thomson Reuters Highly Cited Researcher.
He will advise as Candel advances lead viral immunotherapy candidates CAN-2409 across multiple solid tumors and CAN-3110 for recurrent high-grade glioma, bringing expertise in dendritic cell biology and human immune-response systems.
Candel Therapeutics (Nasdaq: CADL) entered a five-year $130 million term loan facility with Trinity Capital on Oct 14, 2025, with $50 million drawn at closing and access to up to an additional $80 million across three tranches.
The facility carries an initial interest option of 10.25% per annum, a 36-month interest-only period (extendable 12 months upon a commercial milestone), and contains customary covenants and events of default. Candel reported $87.2 million cash as of Sept 30, 2025. Proceeds will refinance an existing loan and fund working capital, initiation of a pivotal phase 3 CAN-2409 NSCLC trial planned for Q2 2026, and prepare for a potential BLA submission in prostate cancer in Q4 2026.
Trinity Capital (Nasdaq: TRIN) committed $130 million in growth capital to Candel Therapeutics (Nasdaq: CADL) on October 14, 2025 to support development of viral immunotherapies.
The funding is earmarked to support clinical development of CAN-2409 and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer pending regulatory approval. Candel's pipeline includes CAN-2409 and CAN-3110 targeting solid tumors (prostate, pancreatic, lung, brain).
Candel has received multiple FDA designations: RMAT for localized prostate cancer, Fast Track for localized prostate and non-small cell lung cancer, and dual Fast Track and Orphan Drug designations for pancreatic and brain cancer programs.
Candel Therapeutics (Nasdaq: CADL) reported encouraging interim phase 1b data for CAN-3110 in recurrent glioblastoma and a related Science Translational Medicine publication on October 8, 2025. Serial multiomic analysis of 97 tumor biopsies from two patients after repeated CAN-3110 dosing showed tumor-to-immune-cell replacement and one complete pathological response despite MRI increases that can mimic progression. Investigators observed expansion of tissue-resident effector memory T cell clonotypes and HLA-presented tumor and viral peptides, supporting viral- and tumor-specific immune activation. Updated median overall survival was 11.8 months (arm A, n=41) and 12.0 months (arm B, n=9). Arm C (n=9) had multiple administrations; no clear benefit beyond 4 injections was seen.
Candel Therapeutics (Nasdaq: CADL) announced it will present multiple updates at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5-9, 2025, National Harbor, Maryland. The company will present two poster abstracts on Nov 7: one on its enLIGHTEN Discovery Platform and one on CAN-2409+valacyclovir immune responses in NSCLC. CEO Dr. Paul Peter Tak will give an invited faculty presentation and participate in a panel to present positive phase 3 CAN-2409 data in localized prostate cancer on Nov 7 at 3:55–5:35 p.m.
Candel Therapeutics (Nasdaq: CADL) presented positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer at ASTRO 2025. The trial, involving 745 patients with intermediate-to-high-risk localized prostate cancer, demonstrated a 30% improvement in disease-free survival (HR 0.7, p=0.0155) and 38% improvement in prostate cancer-specific disease-free survival (HR 0.62, p=0.0046).
Key findings showed CAN-2409's efficacy was consistent across radiation therapy modalities, with significant improvements observed in both moderate hypofractionated EBRT (HR 0.52) and conventional EBRT (HR 0.76). The treatment achieved 80.4% pathological complete response rates compared to 63.6% in the control arm. Grade ≥3 treatment-related adverse events remained similar between treatment and control groups.
The company plans to submit a Biologics License Application in Q4 2026, positioning CAN-2409 as potentially the first major advancement in localized prostate cancer treatment in over 20 years.
Candel Therapeutics (NASDAQ:CADL) announced the acceptance of their abstract for oral presentation at the 2025 ASTRO Annual Meeting in San Francisco. The presentation will showcase results from their Phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer.
Dr. Glen Gejerman from Hackensack University Medical Center will present the findings of the randomized, placebo-controlled study evaluating CAN-2409+Prodrug in combination with standard EBRT for newly diagnosed localized prostate cancer. The presentation is scheduled for September 28, 2025, at 2:30 PM PT. The abstract has also been selected for ASTRO's Science Highlights - Genitourinary Cancer session.